Core Viewpoint - Daoshi Technology (300409.SZ) announced a significant investment in Brain Family Inc. through its subsidiary Hong Kong Jiana, acquiring minority equity in the company by subscribing to Pre-B round preferred shares for $30 million [1] Company Summary - Hong Kong Jiana, a subsidiary of Daoshi Technology, will invest $30 million in Brain Family Inc. to acquire minority shareholder rights [1] - Brain Family Inc. is a leading global company in brain-computer interface technology, possessing unique technological barriers and commercialization capabilities [1] - The core team of Brain Family Inc. includes members from prestigious institutions such as Harvard and MIT, and the company holds over 460 authorized patents [1] - Brain Family Inc.'s core products have received international certifications from FDA and CE, and are widely used in various fields including medical rehabilitation, educational technology, consumer health, human-computer interaction, and entertainment [1]

Group 1 - The A-share market saw a significant rise in brain-computer interface concept stocks, with notable increases including Botao Bio rising over 12%, Innovation Medical hitting the daily limit (5 consecutive days), Sanbo Brain Science increasing over 9%, Nanjing Panda up over 4%, Qisheng Technology up over 3%, and Aipeng Medical up over 2% [1] - Innovation Medical announced its investment in Bole Brain-Computer (Hangzhou) Technology Co., Ltd. (referred to as "Bole Brain-Computer") in early 2021, holding a 40% stake in the company [1] - Bole Brain-Computer focuses on the research and development of core brain-computer interface technologies and the design and production of related products, primarily applied in the medical rehabilitation field [1] - As of the announcement date, Bole Brain-Computer's products have not officially launched, with only a small number of products sold through collaborations with research institutions [1] - The operating losses for Bole Brain-Computer are projected to be 6.60 million yuan and 8.66 million yuan for 2023 and 2024, respectively [1]

Group 1 - The core viewpoint of the news is the significant rise in A-share market stocks related to brain-computer interface concepts, with notable increases in several companies' stock prices [1] - Among the companies, Botao Bio surged over 12%, Innovation Medical reached a daily limit up (5 consecutive days), Sanbo Brain Science increased over 9%, Nanjing Panda rose over 4%, Qisheng Technology gained over 3%, and Aipeng Medical went up over 2% [1] - Innovation Medical announced its investment in Bole Brain-Computer (Hangzhou) Technology Co., Ltd., holding a 40% stake, which focuses on the research and development of core brain-computer interface technologies and related product design for medical rehabilitation [1] Group 2 - As of the announcement date, Bole Brain-Computer's products have not officially launched, with only a small quantity sold through collaborations with research institutions [1] - The projected operating losses for Bole Brain-Computer are 6.60 million yuan in 2023 and 8.66 million yuan in 2024 [1]

Core Viewpoint - Silicon Treasure Technology (300019.SZ) has stated that the company currently does not have any products applied in the brain-computer interface sector [1] Company Summary - Silicon Treasure Technology has clarified its position regarding the development of products for brain-computer interfaces, indicating no current involvement in this area [1]

Core Viewpoint - The stock of Innovation Medical experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days from August 11 to August 13, 2025, but no undisclosed significant information affecting the stock price was found [1] Group 1 - The company confirmed that there were no significant changes in its production operations or external environment, and the controlling shareholder and actual controller did not plan any undisclosed major matters during the abnormal fluctuation period [1] - Innovation Medical holds a 40% stake in Bole Brain Machine (Hangzhou) Technology Co., Ltd., which focuses on the research and development of core brain-machine interface technologies and related product design and production [1] - Bole Brain Machine's products are primarily applied in the medical rehabilitation field, but as of the announcement date, the products have not been officially launched, with only a small number of products sold through collaboration with research institutions [1] Group 2 - The operating losses for Bole Brain Machine were reported at 6.6017 million yuan in 2023 and 8.6641 million yuan in 2024 [1]